A

Amgen

Makes biotech medicines for serious illnesses

Global Pharmacovigilance Manager

Full-TimeUpdated on 10/21/2026
$116.2k - $157.2k/yr+ Discretionary annual bonus + Stock-based long-term incentives
Senior
Bachelor's, Master's, PharmD, PhD, Associate's, MD
Remote in USA
Remote
Biology & Biotech
H1B Sponsorship Available

About the job

Requirements
  • A doctorate degree, or a master's degree and 2 years of industry pharmacovigilance experience, or a bachelor's degree and 4 years of industry pharmacovigilance experience, or an associate's degree and 8 years of industry pharmacovigilance experience, or a high school diploma or GED and 10 years of industry pharmacovigilance experience.
  • Demonstrated experience in signal detection, signal evaluation, signal analysis, and signal management activities.
  • Experience authoring or reviewing aggregate safety reports, including PBRERs, PSURs, DSURs, and Safety Assessment Reports.
  • Experience supporting benefit-risk assessments for investigational or marketed products.
  • Experience developing, maintaining, or supporting Risk Management Plans, REMS, or other risk minimization strategies.
  • Experience using literature surveillance and external data sources to support signal detection and safety assessments.
  • Experience using Argus Safety or other global safety databases and signal management tools.
  • Knowledge of FDA, EMA, ICH, and global pharmacovigilance regulations and guidance.
  • Experience supporting regulatory submissions, inspections, audits, and health authority responses.
  • Clinical development, medical affairs, clinical research, or pharmacovigilance experience supporting products in development and post-marketing settings.
  • Demonstrated clinical and scientific judgment to interpret complex safety data and communicate risk effectively.
  • Ability to influence and lead within a highly matrixed, cross-functional environment.
  • Experience presenting safety assessments and recommendations to governance committees and senior leadership.
  • Strong written, verbal, presentation, and stakeholder management skills.
Responsibilities
  • Lead signal detection, validation, prioritization, evaluation, and management using multiple safety data sources and signal detection methodologies.
  • Conduct scientific and medical evaluation of adverse events and emerging safety concerns from clinical trials, post-marketing surveillance, literature, and external data sources.
  • Perform complex safety analyses and communicate evidence-based recommendations to support product safety decisions.
  • Integrate information from safety databases, clinical studies, literature, epidemiology, and external sources to assess potential safety signals.
  • Support and contribute to benefit-risk evaluations that inform product development, regulatory submissions, labeling updates, and lifecycle management decisions.
  • Collaborate with Global Safety Officers to evaluate safety concerns and recommend risk mitigation strategies.
  • Lead or contribute to planning, preparation, authoring, review, and submission of aggregate safety reports, including PBRERs/PSURs, DSURs, Safety Assessment Reports, regulatory safety responses, and other global pharmacovigilance deliverables.
  • Prepare clear, scientifically sound analyses and conclusions about product safety profiles.
  • Ensure the quality, consistency, and scientific integrity of safety assessments and aggregate reports.
  • Provide strategic safety input into clinical protocols, statistical analysis plans, safety analysis plans, investigator brochures, and clinical study reports.
  • Review safety data presentations, including tables, figures, and listings, and provide recommendations.
  • Participate on study teams and collaborate with Clinical Development partners to support ongoing safety surveillance activities.
  • Contribute to development of safety-related data collection tools and methodologies for clinical studies.
  • Represent Global Patient Safety within safety governance and cross-functional teams.
  • Present safety analyses, emerging signals, benefit-risk assessments, and Global Safety Team recommendations to governance committees and cross-functional decision-making bodies.
  • Collaborate with Clinical Development, Regulatory Affairs, Biostatistics, Medical Affairs, Epidemiology, and other stakeholders.
  • Influence strategic safety decisions through scientific leadership and communication.
  • Contribute to development and execution of global risk management strategies throughout the product lifecycle.
  • Develop and maintain safety content for Risk Management Plans, risk minimization activities, and related regulatory documentation.
  • Support implementation and tracking of risk minimization measures.
  • Evaluate the effectiveness of risk minimization activities and recommend enhancements.
  • Support responses to regulatory inquiries related to risk management activities.
  • Provide strategic safety support for regulatory submissions, health authority interactions, product launches, and lifecycle management initiatives.
  • Partner with Global Safety Officers to develop and execute global safety regulatory strategies.
  • Prepare safety content and supporting documentation for regulatory filings and submissions.
  • Support preparation of responses to regulatory authority questions and requests.
  • Support regulatory inspections, audits, and pharmacovigilance compliance activities while maintaining inspection readiness.
  • Undertake activities delegated by the Qualified Person for Pharmacovigilance as described in the Pharmacovigilance System Master File.
  • Ensure compliance with global pharmacovigilance regulations, GVP guidance, ICH requirements, and internal procedures.
  • Lead or support initiatives to improve pharmacovigilance processes, methodologies, quality, compliance, and operational efficiency.
  • Participate on teams implementing new safety processes, technologies, and methodologies.
  • Provide scientific leadership and mentorship to junior pharmacovigilance scientists and project team members.
  • Contribute to safety strategy discussions supporting oncology, immunology, inflammation, rare disease, and biologic development programs.
  • Perform other duties related to the position as assigned by management or described in applicable procedures.
Desired Qualifications
  • An advanced scientific or healthcare degree is preferred, such as PharmD, PhD, RN, NP, PA, MD, or an equivalent scientific discipline.
  • 5 or more years of pharmacovigilance or drug safety experience in biotechnology, pharmaceutical, or CRO environments.
  • Experience in oncology, immunology, inflammation, rare disease, biologics, or related therapeutic areas.

About the company

Amgen develops and makes biologic medicines, which are drugs built from proteins and antibodies grown in living cells, for serious conditions such as heart disease, cancer, and bone loss. Its anemia drug Epogen, approved in 1989, became one of the biotechnology industry's first blockbuster medicines. Amgen grows these drugs in large tanks called bioreactors, and its products include the cholesterol drug Repatha, the bone-building drug Evenity, and the severe asthma drug Tezspire. It earns money by selling these medicines, mostly through large drug wholesalers that supply hospitals and pharmacies. Amgen was founded in 1980 and is based in Thousand Oaks, California.

Company Size

10,001+

Company Stage

IPO

Headquarters

Thousand Oaks, California

Founded

1980

Get referred to Amgen

See people who can refer or advise you

Simplify Jobs

Simplify's Take

What believers are saying

  • Growth is broad-based: 22 products grew at least 10%, lifting June 2026 quarter revenue 10% to $10.1 billion.
  • Stock grants gained value: Amgen shares rose 27% from January to October 9, 2026, versus 10% for rival Eli Lilly.
  • Many U.S. roles are remote: 145 of Amgen's 615 U.S. job openings in October 2026 were fully remote.

What critics are saying

  • Its 2025 best seller is shrinking: cheaper copies cut bone drug Prolia's sales 32% in the June 2026 quarter.
  • MariTide, Amgen's obesity bet, faces a giant: Lilly's Mounjaro and Zepbound outsold all of Amgen in the June 2026 quarter.
  • Most tech openings are in India: 156 of Amgen's 210 information systems jobs in October 2026 were in Hyderabad.

What makes Amgen unique

  • It copies rivals' blockbusters too: Pavblu, its version of Regeneron's eye drug Eylea, sold $700 million in 2025.
  • Amgen hunts drug targets in a nation's DNA: its Icelandic unit deCODE has genetic data on two-thirds of Iceland's adults.
  • Amgen opened a U.S. cancer-drug class: Blincyto, approved in 2014, was the first to tether immune cells to cancer.

Help us improve and share your feedback! Did you find this helpful?

Benefits

  • Professional Development Budget
  • Conference Attendance Budget

Company News

Yahoo Finance
Oct 20th, 2026
Johnson & Johnson and Amgen beat the market in 2026, but can the dividend stocks keep going?

Johnson & Johnson and Amgen, two dividend stocks that have beaten the broader market this year, could suit investors bracing for a possible crash. J&J's latest quarter beat expectations, and it slightly raised its 2026 guidance. But its medtech unit is struggling, as demand for the Impella heart pump has fallen amid safety questions and a US Class 1 recall. Long-term, it has new drugs, a robotic surgery system approved in the US, and a proposed $5.5 billion talc settlement. It is a Dividend King with 64 straight years of payout increases. Amgen's second-quarter revenue rose 10% to $10.1 billion, despite pressure on Tavneos and falling denosumab sales. It has raised payouts 152% over a decade and offers a 2.3% forward yield, against 1.1% for the S&P 500.

Yahoo Finance
Oct 17th, 2026
Amgen raises 2026 revenue forecast to $38.8B as shares gain 15.2%

Amgen raised its fiscal 2026 revenue forecast on August 4 to $38.8 billion at the midpoint, up 2.6% from $37.8 billion. Adjusted earnings per share guidance rose to $22.90 from $22.40. Six key growth drugs grew 26% from a year earlier and made up nearly 70% of product sales in the June quarter. Repatha sales rose 37% to $953 million, offsetting a 33% drop in Prolia and XGEVA sales as biosimilar copies launched. Total revenue rose 10%. The stock has gained 15.2% since the release, against 1.9% for the S&P 500. It closed at $434.03 on October 15, above both its 50-day and 200-day averages. Reaching the midpoint requires $20.1 billion in the second half. Amgen's next report is expected around November 3.

Yahoo Finance
Oct 8th, 2026
Amgen invests $2.6B in manufacturing for MariTide obesity drug ahead of Phase III results

Amgen is testing MariTide, an experimental obesity drug designed to be dosed monthly or less frequently. The therapy has advanced into late-stage Phase III trials, with nine studies currently running and three more planned. Executives reported strong enrolment during the company's second-quarter 2026 earnings call on 4 August 2026. Amgen expects capital spending of about $2.6 billion in 2026, partly to scale manufacturing capacity for MariTide's eventual launch. The company is investing across its US manufacturing sites in North Carolina, Ohio, and Puerto Rico. Amgen stock has returned 44% over the past twelve months, outpacing the S&P 500's 17.1% gain. The company reported $38.1 billion in revenue over the last twelve months, up from $34.9 billion a year earlier.

Yahoo Finance
Sep 29th, 2026
Amgen lifts dividend 6%, but eroding Prolia and Enbrel sales shift focus to MariTide Phase 3

Amgen raised its quarterly dividend 6% to $2.52 per share, marking its 14th consecutive annual increase since starting payouts in 2011. The biotech now pays $10.08 annually, yielding 2.36% at current share prices of $418.13. The dividend appears well covered. Amgen generated $8.1 billion in free cash flow in 2025 against $5.1 billion in dividend payments. Second quarter 2026 free cash flow reached $3.5 billion whilst dividends consumed $1.4 billion. However, biosimilar competition is eroding legacy revenue. Prolia and XGEVA sales dropped 33% whilst Enbrel fell 37%. The company carries $57 billion in debt. Future dividend growth may hinge on Phase 3 results for MariTide, Amgen's obesity candidate. The company follows a steady raise pattern similar to Johnson & Johnson, contrasting with Pfizer's post-COVID payout struggles.

Yahoo Finance
Sep 26th, 2026
Vertex and Amgen deliver promising pipeline updates as both outperform market

Vertex Pharmaceuticals reported strong second-quarter results, with revenue rising 12% year-over-year to $3.33 billion and earnings per share climbing 8% to $4.31. The company posted positive Phase 2b results for inaxaplin, an experimental treatment for APOL1-mediated kidney disease, showing it reduced proteinuria in patients with modest protein levels and those with type 2 diabetes. Vertex expects approval for povetacicept, a treatment for IgA nephropathy, by November. The company continues diversifying beyond its core cystic fibrosis franchise, which provides predictable revenue as patients require lifelong treatment. Meanwhile, Amgen has also outperformed the broader market this year, though specific recent developments were not detailed in the source material.